Emergent BioSolutions logo
|Headquarters||Rockville, Maryland, United States|
|Key people||Daniel J. Abdun-Nabi, CEO & President|
|Products||BioThrax (Anthrax Vaccine Adsorbed)|
|Revenue||US$273.38 million (2012)|
|Net income||US$18.14 million (2012)|
Emergent BioSolutions (NYSE: EBS) is a multinational specialty biopharmaceutical company headquartered in Rockville, Maryland. It develops vaccines and therapeutics for infectious diseases, oncology and autoimmune disorders. The company has two divisions: a Biodefense division for counter-Anthrax products and a Biosciences division to treat some forms of autoimmune and inflammatory disorders and cancer. It was founded as BioPort Corporation in 1998, and renamed Emergent BioSolutions in 2004. Since the early 2000s, Emergent has expanded its product development, including research and development of products through joint ventures with its most well-known product being an anthrax vaccine.
On August 2, 2013, Emergent acquired the Healthcare Protective Products Division (HPPD) of Bracco Diagnostics Inc. In doing so, Emergent acquired a product known as RSDL, which is a lotion used to decontaminate skin immediately after someone becomes exposed to certain chemical warfare agents.
In 1998, the BioPort Corporation was founded to acquire an anthrax vaccine manufacturing facility in Lansing, Michigan, and other assets of the Michigan Biologics Products Institute, formerly owned by the Michigan Department of Public Health. In addition to the Lansing facility, BioPort acquired the license to produce anthrax vaccine for the U.S. Department of Defense. Emergent acquired, Antex Biologics Inc., a pharmaceutical research and development company, in 2003. The following year, a corporate restructuring turned BioPort and its subsidiary, Antex Biologics, into wholly owned subsidiaries of Emergent BioSolutions Inc. Microscience Ltd. (based in the United Kingdom) was acquired in 2005. In August 2006, Emergent purchased Vivacs GmbH, a biotechnology company based in Munich, Germany. A few months later, Emergent held its initial public offering (IPO) on the New York Stock Exchange.
In 2006 and 2007, Emergent developed medications and vaccines for the treatment of typhoid, hepatitis B and streptococcus, for which development is no longer being pursued. As of July 2011[update], Emergent's product development pipeline includes product candidates targeting infectious diseases, oncology and autoimmune disorders. On March 6, 2008, Emergent completed the acquisition of a group of anthrax monoclonal antibodies from Avanir Pharmaceuticals. On May 5, 2008, Emergent acquired patents and processes of VaxGen, Inc., of Livermore, California, including VaxGen's anthrax vaccine program. Emergent acquired Trubion Pharmaceuticals in October 2010, providing Emergent with oncology and autoimmune disease treatment candidates. In 2011, it acquired the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy from TenX BioPharma, Inc.
In June 2012, Emergent, along with Novartis and the Texas A&M University System was selected by the U.S. Department of Health and Human Services as one of the three Centers for Innovation in Advanced Development and Manufacturing. The public-private partnership granted Emergent $163 million over eight years to assist in the development of countermeasures for health, nuclear and radiological epidemics. Fuad El-Hibri, the former CEO of Emergent BioSolutions led the company since its founding as BioPort Inc. until his retirement on April 1, 2012. He continues to serve as the executive chairman of Emergent BioSolutions’ board of directors.
On February 21, 2014, Emergent announced that it acquired Cangene Corporation at a purchase price of $222 million. Cangene’s flagship marketed product is WinRho, which is indicated for immune thrombocytopenic purport (a blood disorder) and hemolytic disease of the newborn. The acquisition was first announced by Emergent on December 11, 2013.
Emergent BioSolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of disease. It manufactures BioThrax (Anthrax Vaccine Adsorbed), a vaccine licensed by the U.S. Food and Drug Administration. Following a study by scientists from the Centers for Disease Control and Prevention, on December 19, 2008, Emergent received final FDA licensing for use of BioThrax five doses for intramuscular injection. Later in 2009, Emergent received approval from the FDA to extend the shelf life of its anthrax vaccine from three to four years. BioThrax was approved for distribution in the United States. BioThrax has received marketing approval in India, Singapore and Germany.
- Emergent is the 13th largest pharmaceutical company (by market capitalization) in the New York Stock Exchange.
- "Emergent BioSolutions Corporate Governance". Emergent BioSolutions. Retrieved 8 July 2013.
- Ramstack, Tom (16 October 2007). "BioSolutions posts healthy progress". The Washington Times. p. C10.
- "Emergent Biosolutions Inc. Financial Statements". Google Finance. Retrieved 12 July 2013.
- "EMERGENT BIOSOLUTIONS INC (EBS:New York): Company Description [Page 3] - Businessweek". investing.businessweek.com. Retrieved 28 September 2012.
- Bryan Cohen, "Emergent BioSolutions closes on acquisition of Bracco Diagnostics division", Vaccine News Daily, August 6, 2013. (Retrieved August 13, 2013)
- "Emergent BioSolutions Closes on Its Acquisition of Healthcare Protective Products Division from Bracco Diagnostics Inc.", Yahoo Finance press release, August 2, 2013. (Retrieved August 13, 2013)
- "Lansing laboratory may begin anthrax vaccine shipments". The Michigan Daily. 23 January 2002. Retrieved 30 June 2011.
- Williams, Thomas D. (18 May 2001). "Shays: Pentagon Acted Inappropriately". The Hartford Courant. Retrieved 30 June 2011.
- Tinder, Paul (November 10, 2009). "Emergent BioSolutions appoints Jackson as chief scientific officer". Vaccine News Daily. Retrieved 8 July 2013.
- Gamat, Gloria (September 2, 2006). "Emergent BioSolutions, Inc.’s BioThrax® (Anthrax Vaccine Adsorbed), Certified by U.S. Department of Homeland Security As An Approved Product For Homeland Security". Pharma Gazette. Retrieved 8 July 2013.
- "Emergent acquires vaccine company.". BIOTECH Patent News. 1 June 2005. ISSN 0898-2813.
- "Emergent BioSolutions mit verstärkter Präsenz in Deutschland". bionity.com (in German). Bionity. August 7, 2006. Retrieved 8 July 2013.
- Cowan, Lynn (15 November 2006). "Stock of vaccine maker has weak opening after IPO". Dow Jones Newswires. The Associated Press.
- "Form S1/A Emergent BioSolutions Inc.". Corporate IR.net. Thomson Reuters. 30 October 2006. Retrieved 20 July 2011.
- "Emergent BioSolutions Portfolio as of July 2011" (PDF). Emergent BioSolutions. July 2011. Retrieved 11 July 2011.
- "Avanir Divests Anthrax mAb Program to Emergent BioSolutions in Deal Worth $1.75M". Genetic Engineering & Biotechnology News. 6 March 2008. Retrieved 12 October 2011.
- "VaxGen sells anthrax vaccine candidate to Emergent BioSolutions". Forbes. Thomson Reuters. 5 May 2008. Retrieved 11 July 2011.
- "VaxGen wraps up sale of anthrax assets". San Francisco Business Times. 5 May 2008. Retrieved 11 July 2011.
- "Emergent BioSolutions Completes Acquisition Of Trubion Pharmaceuticals". The Street. 28 October 2010. Retrieved 12 July 2011.
- "Emergent BioSolutions Continues Expansion into Cancer with mAb Acquisition from TenX". Genetic Engineering & Biotechnology News. 6 June 2011. Retrieved 22 July 2011.
- "Emergent licenses flu vaccine for new federal biodefense center". Gazette.net. 4 January 2013. Retrieved 25 January 2013.
- Shapiro, Andy (29 May 2008). "Md. firm to buy Protein Sciences". New Haven Register.
- "Emergent BioSolutions CEO joins board of U.S. Chamber of Commerce". Washington Business Journal. 13 June 2010.
- Overly, Steven (21 December 2011). "Emergent CEO to step down in 2012". Capital Business Blog. The Washington Post. Retrieved 30 March 2012.
- Eckert, Barton (21 December 2011). "Emergent BioSolutions Fuad El-Hibri to retire as CEO". Washington Business Journal. Retrieved 30 March 2012.
- Kevin James Shay (30 March 2012). "Emergent’s Fuad El-Hibri, an entrepreneur at heart". Gazette.net. Retrieved 30 March 2012.
- "Cangene Receives Court Approval of Plan of Arrangement for Acquisition by Emergent BioSolutions”. Wall Street Journal. 2014-02-18 (Retrieved 2014-02-21)
- "Emergent BioSolutions Completes Acquisition of Cangene Corporation” (Press release). Emergent BioSolutions. 2014-02-21 (Retrieved 2014-02-21)
- Overly, Steven. "Emergent BioSolutions pays $222M to acquire life sciences firm Cangene Corp.” The Washington Post. 2013-12-11 (Retrieved 2014-02-21)
- "Emergent BioSolutions to Acquire Cangene Corporation” (Press release). Emergent BioSolutions. 2013-12-11 (Retrieved 2014-02-21)
- "Emergent BioSolutions Secures Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax". Health & Beauty Close-Up. 9 November 2010.
- Echols, Tucker (14 July 2010). "Emergent BioSolutions wins $107M HHS contract". Washington Business Journal.
- Lauerman, John (30 September 2008). "Emergent's Anthrax Vaccine Effective With Fewer Doses in Study". Bloomberg. Retrieved 11 July 2011.
- "Emergent BioSolutions Gets FDA Nod For Anthrax Vaccine supplemental BLA - Update", RTT News, December 19, 2008. Retrieved August 13, 2013.
- "Emergent BioSolutions Gets FDA Nod For Anthrax Vaccine supplemental BLA - Update". RTT News. 19 December 2008. Retrieved 11 July 2011.
- "Local Briefing". The Washington Post. 13 February 2009. Retrieved 11 July 2011.
- Clabaugh, Jeff (24 June 2011). "Emergent gets entry to Singapore". Washington Business Journal. Retrieved 22 July 2011.
- "Emergent BioSolutions Receives Paul-Ehrlich-Institut Approval to Market BioThrax in Germany", Yahoo Finance press release, July 1, 2013. Retrieved August 13, 2013.
- "Emergent BioSolutions increases 0.6% on weak volume”, News Bites US Markets, 30 May 2013, Retrieved 07 June 2013 via Nexis